Apple's Hidden Blood Sugar Study: What Big Tech's Move Into Diabetes Care Means

Apple quietly ran a study in 2024 to test a blood-sugar monitoring app. The project is a clear signal that major technology companies are moving into diabetes management—a field that is changing rapidly as both monitoring devices and insulin delivery systems evolve.

According to Bloomberg, the study aimed to explore how Apple could build consumer-friendly tools around blood-sugar data. This timing matters because the continuous glucose monitoring (CGM) market—devices that track blood glucose 24/7 without finger pricks—is expanding well beyond people with diabetes who need insulin.

When Glucose Monitors Went Over-the-Counter

Until recently, glucose monitors required a doctor's prescription. That changed in August 2024 when Dexcom launched Stelo, a CGM device you can buy without a prescription. The device targets people with type 2 diabetes who do not use insulin—a much larger population than traditional prescription-only CGM users.

This shift is significant. Earlier devices like Dexcom's G5 Mobile and Abbott's FreeStyle Libre family were designed for people actively managing diabetes with medication. Stelo opens the door to people who want to track their glucose patterns but haven't been formally diagnosed or don't need insulin—a market that looks attractive to consumer tech companies.

Combining Sensors and Pumps Into One Device

Meanwhile, hardware makers are packing more capability into smaller form factors. Pharmasens, a Swiss company, demonstrated a patch device called niia signature that combines a glucose sensor and insulin pump in one unit worn for five days. Medtronic received approval in Europe for its MiniMed 780G, a system that automatically adjusts insulin delivery based on glucose readings. The FDA also approved the Eversence device, following a study of 71 people with type 1 and type 2 diabetes.

These are not minor tweaks. The shift toward all-in-one wearable systems makes diabetes management simpler and reduces the friction that often keeps people from sticking with monitoring routines.

Beyond Simple Blood Sugar Numbers

The diagnostic conversation is broadening beyond glucose alone. Researchers are looking at markers like 1,5-anhydroglucitol (1,5-AHG)—a blood compound that tracks average glucose over roughly the last two weeks—and leptin, a hormone linked to insulin resistance and body weight regulation. These biomarkers could provide a richer picture of metabolic health and long-term complication risk.

Today, doctors diagnose type 2 diabetes using fasting blood sugar, HbA1c (which reflects average glucose over three months), glucose tolerance tests, and random blood sugar measurements. The laboratory could add more precision over time.

How Tech Companies Are Reshaping Medical Devices

The broader context here is worth pausing on. We have seen this pattern before—when smartphone makers entered personal health tracking. Your phone now counts steps, monitors your heart rate, and checks blood oxygen. Each time a consumer electronics company moves into health, it brings lower costs, easier-to-use interfaces, and access for people who wouldn't normally see a doctor. But it also brings regulatory complexity and the risk of data becoming a product rather than a private medical record.

Apple's position is particularly strong. The company already has a Health app ecosystem, years of experience embedding sensors into wearables, and the scale to negotiate with regulators and healthcare systems. If Apple builds a glucose app that works with its Watch, it could make continuous monitoring as routine as checking your heart rate—and that would reshape the entire diabetes device market.

For established manufacturers like Medtronic and Abbott, which have spent decades building relationships with doctors and hospitals, this is disruptive. Apple and other tech giants operate on different cost structures, own distribution through their platforms, and have different ideas about what happens to health data. The old rules may not hold.

What This Means for Patients and Doctors

For healthcare providers and patients, this shift presents genuine benefits and real questions. Broader access to continuous glucose monitoring could help people catch metabolic problems earlier and manage diabetes better. But it also means more data from consumer devices—which may be less reliable than medical-grade equipment—and the need for new ways to interpret and act on that information.

The clinical validation work is substantial. Before hospitals and doctors can confidently act on data from new biomarkers or consumer devices, those tools need to be tested in real patients, their results need to be standardized across different companies, and clinical guidelines need to catch up. That takes time.

The diabetes technology landscape is heading toward significant change. The question is not whether technology companies will enter this space—Apple and others have already made clear they will. The real challenge is how quickly they can satisfy regulators while building tools that actually fit into how doctors and patients work, rather than complicating care pathways that already exist.